Benzodiazepinler ve Yeni Tasarım Benzodiazepinler

Authors

Gözde Aktürk
https://orcid.org/0000-0003-1343-4361
Şule Kalkan

Synopsis

Benzodiazepines act as allosteric modulators on GABA_{A} receptors in the central nervous system, increasing GABA affinity, and are widely used clinically for their anxiolytic, hypnosedative, muscle relaxant, and anticonvulsant properties. Metabolized in the liver via microsomal oxidation (Phase I) and glucuronidation (Phase II) reactions, these drugs are categorized by their duration of action into very short, short, intermediate, and long-acting groups. Despite possessing a high therapeutic index, long-term administration of benzodiazepines can induce physical and psychological dependence, tolerance, and severe withdrawal symptoms. Although regulated under green prescriptions in Turkey, their abuse potential remains significant. Recently, novel psychoactive substances (NPS) such as phenazepam, etizolam, and flubromazepam have emerged in online markets under terms like "designer benzodiazepines" or "research chemicals" without medical authorization. These novel compounds pose serious public health threats by substantially increasing the risks of fatal respiratory depression and coma, particularly when co-ingested with opioids or alcohol. Furthermore, as immunoassay screenings on biological matrices can produce false positives due to cross-reactivity with drugs like sertraline or efavirenz, or false negatives from low concentrations, chromatographic verification methods like LC-MS and GC-MS alongside forensic-clinical toxicological evaluations are of paramount importance.

References

KAYAALP O. Akılcıl Tedavi Yönünden Tıbbi Farmakoloji. Pelikan. 2018.

Rang H, Dale M, Ritter J, et al. Rang and Dale’s Pharmacology (Ninth ed.). London: Churchill Livingstone Elsevier. 2019.

European Monitoring Centre for Drugs and Drug Addiction. 2018. The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe.https://www.emcdda.europa.eu/topics/pods/benzodiazepines.

European Monitoring Centre for Drugs and Drug Addiction. 2021. New benzodiazepines in Europe – a review. https://www.emcdda.europa.eu/publications/technical-reports/new-benzodiazepines-europe-review_en.

Mehdi T. Benzodiazepines revisited. British Journal of Medical Practitioners. 2012; 5(1), 501.

Moosmann B, Auwärter V. Designer benzodiazepines: Another class of new psychoactive substances. Handbook of Experimental Pharmacology. 2018. 383-410. doi:10.1007/164_2018_154.

Zawilska JB, Wojcieszak J. An expanding world of new psychoactive substances—designer benzodiazepines. [Online] NeuroToxicology. 2019; 73, 8-16. doi:10.1016/j.neuro.2019.02.015.

Orsolini L, Corkery JM, Chiappini S, et al. ‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip Reports. Current Neuropharmacology. 2020; 18, 809-837. doi:10.2174/1570159x18666200110121333.

Mutlu E, Aşicioğlu F. Abuse of prescribed psychoactive drugs. Anadolu Psikiyatri Dergisi. 2020; 21(2), 195-202. doi:10.5455/apd.53469.

Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. [Online] Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. 2013. doi:10.1176/appi.books.9780890425596.893619

Gulec G, Kosger F, Essizoglu A. Alcohol and Substance Use Disorders in DSM-5. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry. 2015; 7(4), 448-460. doi:10.5455/cap.20150325081809.

Türkiye Cumhuriyeti Anayasası. 2709 sayılı kanun. 2018. https://www.tbmm.gov.tr/anayasa.htm_2018.pdf.

Türk Ceza Kanunu. 5237 sayılı Türk Ceza Kanunu. 2004. https://www.mevzuat.gov.tr/MevzuatMetin/1.5.5237.pdf.

Katzung BG. Basic & Clinical Pharmacology, Fourteenth Edition. Basic and Clinical Pharmacology. 2018.

Gilman AG. Goodman & Gilman’s The Pharmacological Basis of Therapeutics Thirteenth Edition. Mc Graw Hill Education. 2018.

DRUGDEX. [Online] IBM Micromedex [Electronic version]; www.micromedexsolutions.com.

Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: A future for subtype-selective GABAA receptor modulators?. [Online] Advances in Pharmacological Sciences. 2012. doi:10.1155/2012/416864

Qriouet Z, Qmichou Z, Bouchoutrouch N, et al. Analytical Methods Used for the Detection and Quantification of Benzodiazepines. [Online] Journal of Analytical Methods in Chemistry. 2019. doi:10.1155/2019/2035492.

Nasir Uddin M. An Overview on Total Analytical Methods for the Detection of 1,4-Benzodiazepines. Pharmaceutica Analytica Acta. 2014; 5(6), 1000303. doi:10.4172/2153-2435.1000303..

Moeller KE, Lee KC, Kissack JC. Urine drug screening: Practical guide for clinicians. [Online] Mayo Clinic Proceedings. 2008;83(1):66-76. doi:10.4065/83.1.66.

Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: A review. [Online] Journal of Analytical Toxicology. 2014;38:387–396. doi:10.1093/jat/bku075.

Fraser AD, Howell P. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. Journal of Analytical Toxicology. 1998; 22(1), 50-54. doi:10.1093/jat/22.1.50.

Nasky KM, Cowan GL, Knittel DR. False-positive urine screening for benzodiazepines: An association with sertraline? A two-year retrospective chart analysis. Psychiatry. 2009;6(7):36–39.

Blank A, Hellstern V, Schuster D, et al. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clinical Infectious Diseases. 2009; 48:1787–9. doi:10.1086/599109.

Gunn, NI. Negative Urine Drug Screen in a Patient with Chronic Benzodiazepine Use. Proceedings of UCLA Healthcare, 20. 2016.

Beck O, Stephanson N, Sandqvist S, et al. Detection of drugs of abuse in exhaled breath using a device for rapid collection: Comparison with plasma, urine and self-reporting in 47 drug users. Journal of Breath Research. 2013; 7(2), 026006. doi:10.1088/1752-7155/7/2/026006.

Vindenes V, Lund HME, Andresen W, et al. Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers. Forensic Science International. 2012; 165–171. doi:10.1016/j.forsciint.2012.01.001

Lee S, Han E, In S, et al. Determination of illegally abused sedative-hypnotics in hair samples from drug offenders. Journal of Analytical Toxicology. 2011; 35(5), 312-315. doi:10.1093/anatox/35.5.312

Marin SJ, Merrell M, McMillin GA. Drugs of abuse detection in meconium: A comparison between ELISA and biochip microarray. Journal of Analytical Toxicology. 2011; 35(1), 40-45. doi:10.1093/anatox/35.1.40

Mayo Clinic Laboratories. Benzodiazepines. https://www.mayocliniclabs.com /test-info/drug-book/benzodiazepines.html

U.S Food & Drug Administration (FDA). 2020. Benzodiazepine Drug Class: Drug Safety Communication - Boxed Warning Updated to Improve Safe Use. https://www.fda.gov/safety/medical-product-safety-information/benzodiazepine-drug-class-drug-safety-communication-boxed-warning-updated-improve-safe-use.

S. Anna Gandra S, D Almeida AL, M. Teixeira Z. Benzodiazepines Dependence: Addiction to Legally Prescribed Substances. Journal of Forensic Psychology. 2019; 4:149.doi:10.35248/2475-319x.19.4.149.

Özgen A, Birsöz S. Benzodiazepinler “Yararlanım ve Kötü Kullanım Ölçütleri. Bağımlılık Dergisi, 1(2), 89-94. 2000.

Tae Woo Park, MD Ms. Benzodiazepine use disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis - UpToDate. uptodate.

Association AP, others. Diagnostic and Statistical Manual of Mental Disorders. 4th text revision ed. Washington, DC: American Psychiatric Association. 2000.

Gündüz N. 2019. Yasa dışı madde kullanımlarına adli psikiyatrik yaklaşımlar. Naile Esra Saka (Ed). Adli Tıp ve Adli Bilimlerde Klinik Uygulamalara Bakış içinde (s. 295 – 309). Akademisyen Kitabevi.

Çöpür M, Eryılmaz A, Çakmak D. Alkol, madde kullanımı ve yasal sorunlar. Okmeydanı Tıp Dergisi, 2014; 30(Ek sayı 2), 84-88. doi:10.5222/otd.supp2.2014.084.

Denetimli Serbestlik Hizmetleri Kanunu. 5402 sayılı Denetimli Serbestlik Hizmetleri Kanunu. 2005. https://www.mevzuat.gov.tr/MevzuatMetin/1.5.5402.pdf.

O’Connell CW, Sadler CA, Tolia VM, et al. Overdose of etizolam: The abuse and rise of a benzodiazepine analog. [Online] Annals of Emergency Medicine. 2015; 65(4),465-466. doi:10.1016/j.annemergmed.2014.12.019.

Pettersson Bergstrand M, Helander A, Hansson T, et al. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Testing and Analysis. 2017; 9, 640–645 doi:10.1002/dta.2003.

Švidrnoch M, Boráňová B, Tomková J, et al. Simultaneous determination of designer benzodiazepines in human serum using non-aqueous capillary electrophoresis – Tandem mass spectrometry with successive multiple ionic – Polymer layer coated capillary. Talanta. 2018;176, 69–76. doi:10.1016/j.talanta.2017.08.010.

Pettersson Bergstrand M, Beck O, Helander A. Urine analysis of 28 designer benzodiazepines by liquid chromatography–high-resolution mass spectrometry. Clinical Mass Spectrometry. 2018; 10, 25–32. doi:10.1016/j.clinms.2018.08.004.

Andersson M, Kjellgren A. The slippery slope of flubromazolam: Experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. NAD Nordic Studies on Alcohol and Drugs. 2017; 34(3), 217-229. doi:10.1177/1455072517706304.

Published

November 4, 2021

License

License